Zobrazeno 1 - 10
of 597
pro vyhledávání: '"HER2 amplification"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundNon-small cell lung cancer (NSCLC) with human epidermal growth factor receptor 2 (HER2) alterations poses a substantial treatment challenge. Current HER2-targeted therapies offer limited efficacy. Antibody-drug conjugates (ADCs) targeting H
Externí odkaz:
https://doaj.org/article/79110852a5b34f5eb7e04f7cabc7c5b3
Autor:
Samuel A. Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J. Montero, Corey Lipchik, Melanie Finnigan, Rachel C. Jankowitz, Mohamad A. Salkeni, Sai K. Maley, Shannon L. Puhalla, Fanny Piette, Katie Quinn, Kyle Chang, Rebecca J. Nagy, Carmen J. Allegra, Kelly Vehec, Norman Wolmark, Peter C. Lucas, Ashok Srinivasan, Katherine L. Pogue-Geile
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-13 (2024)
Abstract Background We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer patients. Patients with ERBB2 amplification in ctDNA had deeper and more dura
Externí odkaz:
https://doaj.org/article/c30874be81f04b78be67858f937fdb82
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroudHuman epithelial growth factor receptor 2 (HER2) amplification is an important mechanism of acquired resistance to anti-epidermal growth factor receptor (EGFR) therapy in non-small cell lung cancer (NSCLC) patients. For patients with both EG
Externí odkaz:
https://doaj.org/article/bdc2fb16a5fd4223b16d23794361fef7
Publikováno v:
Pharmacogenomics and Personalized Medicine, Vol Volume 17, Pp 1-11 (2024)
Hongyi Zhou,1,* Xueping Cui,2,* Leilei Zhu,1 Zhuoqun Xu,1 Zhuo Wang,3 Jianfeng Shao4 1Department of Urology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, Jiangsu Province, 214023, People’s Republic of China;
Externí odkaz:
https://doaj.org/article/a300105b520549b097f58708cab61a72
Autor:
Nikolay Grachev, Gavriil Rabaev, Ashot Avdalyan, Igor Znamenskiy, Dmitry Mosin, Dmitry Ustyuzhanin, Gennady Rabaev, Martin Lužbeták
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 142-149 (2024)
Introduction: Lacrimal sac squamous cell carcinoma (SCC) is a rare tumor. Only 241 cases of lacrimal sac SCC have been reported in the literature. However, the detailed molecular profile of this tumor is unknown. Case Presentation: Fifty-seven-year-o
Externí odkaz:
https://doaj.org/article/74767fbc933147eda1a2d2df800fbeb8
Autor:
Xiaoqian Jing, Zhiping Luo, Jiayan Wu, Feng Ye, Jianfang Li, Zijia Song, Yaqi Zhang, Minmin Shi, Huaibo Sun, Yi Fang, Yimei Jiang, Xiaopin Ji
Publikováno v:
Cancer Medicine, Vol 12, Iss 24, Pp 21905-21919 (2023)
Abstract Background Anti‐PD1/PD‐L1 antibody plus human epidermal growth factor receptor 2 (HER2) antibody and chemotherapy have become the new first‐line therapy for HER2 overexpression‐positive advanced gastric cancers (GC), suggesting that
Externí odkaz:
https://doaj.org/article/1c31765080b142c8ae6e5f9fd4835ace
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Afsaneh Barzi, Caroline M. Weipert, Carin R. Espenschied, Victoria M. Raymond, Andrea Wang-Gillam, Mohammad Amin Nezami, Eva J. Gordon, Daruka Mahadevan, Kabir Mody
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
PurposeDespite accumulating data regarding the genomic landscape of pancreatic ductal adenocarcinoma (PDAC), olaparib is the only biomarker-driven FDA-approved targeted therapy with a PDAC-specific approval. Treating ERBB2(HER2)-amplified PDAC with a
Externí odkaz:
https://doaj.org/article/e7677069cab2423eb1241b17d63bdd06
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100603- (2023)
Despite the high activity of selective RET inhibitors in RET-driven NSCLC, resistance eventually develops and there is unmet need to better define therapeutic options for patients. This is a case of a patient initially thought to have no targetable a
Externí odkaz:
https://doaj.org/article/c6d38b4552ad4ca8b91fe7e2a64a4418
Autor:
Laura Morsberger, Aparna Pallavajjala, Patty Long, Melanie Hardy, Rebecca Park, Rebecca Parish, Azin Nozari, Ying S. Zou
Publikováno v:
Cancer Cell International, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Human epidermal growth factor receptor 2 (HER2) positive breast carcinomas due to HER2 amplification are associated with aggressive behavior and a poor prognosis. Anti-HER2-targeted therapies are widely used to treat HER2-positive
Externí odkaz:
https://doaj.org/article/c7a89e5d14784cbd89fc714100853ba5